Full-Service Commercial

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk. Opportunities for outsourcing some—or all—of a company’s commercial operations can be an option, but many companies have misconceptions about the highly ...